Date:8/5/2009

Average US Rx Annual Sales CER Growth(1) Market Product Sales $M Growth(2) Growth(3) (2) Share(1) Specialty Pharmaceuticals VYVANSE 114.2 75% 75% 80% 12.1% ADDERALL XR 67.4 -77% -77% -48% 11.0% DAYTRANA 14.9 -34% -34% -14% 1.4% EQUASYM 4.9 n/a n/a n/a(5) n/a(5) LIALDA / MEZAVANT 54.6 71% 73% 53% 15.9% PENTASA 54.0 21% 21% -2% 15.9% FOSRENOL 49.6 17% 26% -3% 7.8% XAGRID 20.7 0% 12% n/a(5) n/a(5) Human Genetic Therapies ELAPRASE 85.3 6% 15% n/a(4) n/a(4) REPLAGAL 44.4 -1% 14% n/a(5) n/a(5) FIRAZYR 1.5 n/a n/a n/a(5) n/a(5)

(1) Product specific prescription data is provided by IMS Health ("IMS") National Prescription Audit, a leading global provider of business intelligence for the pharmaceutical and healthcare industries. All other US market share data stated in the text below is also provided by IMS.

(2) Compared to Q2 2008.

(3) CER growth is calculated after restating Q2 2009 results using Q2 2008 average foreign exchange rates.

    (4) IMS Data not available.
    (5) Not sold in the US.
    Specialty Pharmaceuticals
    US ADHD market share

Shire's share of the total US ADHD market for the three months to June 30, 2009 declined by approximately 8 percentage points to 24.5% (2008: 32.3%), following the launch by Teva in
'/>"/>

SOURCE Shire Plc Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
Related biology technology :

1. Doctors in New Hampshire Now Treating Cancer with Non-Invasive Image-Guided Radiosurgery Using Novalis Tx(TM) Technology
2. The Crohns & Colitis Foundation of America and Shire Launch Virtual IBD March on the Hill to Increase Funding for Digestive Disease Research
3. Shire begins the year with a strong performance
4. Shire plc: Results of the Annual General Meeting Held on April 28, 2009
5. Shire plc: First Quarter 2009 Results Date Notification - April 30, 2009
6. Shire Files Lawsuit Against Natco Pharma for Infringement of FOSRENOL(R) (lanthanum carbonate) Patents
7. Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD
8. Publication of Shire plcs Annual Report 2008
9. Shires Project Playground Gives Boost to Philadelphia
10. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
11. Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents